MWG Biotech receives Frost & Sullivan 2004 Technology Innovation Award for its Microarray Technology
Ebersberg. MWG Biotech AG has received the renowned Frost & Sullivan 2004 Technology Innovation Award in the field of microarray technology. The Award recognises MWG Biotech's high degree of technological innovation and the strong commercial potential for its HPSF® synthesis technology in microarray applications. This technology is proven to produce high quality (purified and salt-free) oligonucleotides much faster when compared to existing HPLC based approaches.
The Award also recognises MWG Biotech's ongoing technological achievement and rapid process improvement. In the award text Frost & Sullivan says, "For instance, [MWG Biotech] is currently developing MWG-HYPUR oligos. The process is based on a non-toxic hydrogel purification technique that removes n-1 products and depurinations from short and longmer oligonucleotides. When introduced, this technology is likely to outperform conventional polyacrylamide gel electrophoresis in terms of both quality and reproducibility".
"We are extremely proud of this Award," says Thomas Becker, CEO of MWG Biotech AG. "It clearly proves our innovative strength and the market leadership of our oligonucleotides as well as the valuable contribution they make to the production of our reliable, high quality MWG catalog and custom microarrays."
Frost & Sullivan's Award for Technology Innovation is bestowed upon a company that has carried out new research which has resulted in innovations that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. The Award recognises the quality and depth of a company's research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavour.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Xceleron scientific advisory board expanded

Food from CO2 - Arkeon Biotechnologies, a Viennese startup, uses gas fermentation technology to convert CO2 into food products
Emerging gene editing approach seeks broad spectrum crop disease resistance

New biologically derived metal-organic framework mimics DNA

Scientists identify rare gene variants which confer up to 6-fold increase in risk of obesity - Genetic variants reveal new biological mechanism regulating appetite control
Scientists develop strategy to rapidly describe outbreak strains with next-generation DNA sequencing

Applied Analytics, Inc. - Burlington, USA

New solution for stem cell manufacturing - A unique 3D printed system for harvesting stem cells from bioreactors
Specialist Business Unit of the University of Nottingham Spins-Out to Form New R&D Oncology Company
Increasing Interest in Cholesterol-lowering Treatment Drive Phytosterol Sales
